Profile Previews

Get a glimpse into our company and investor data—powered by the PitchBook Platform

Celdara Medical (OnCyte)

M&A STATUS
M&A LATEST DEAL TYPE
1 FINANCING ROUNDS
Description

Developer of treatments in the field of immuno-oncology. The business unit has developed the most advanced autologous CAR (chimeric antigen receptor) T-Cell drug candidate uses a specific human Natural Killer cell receptor that targets tumor antigens expressed in most liquid and solid cancers.

Ownership Status
Acquired/Merged
Financing Status
Corporate Backed or Acquired
Primary Industry
Biotechnology
Other Industries
Drug Discovery
Acquirer
Primary Office
  • Lebanon, NH
  • United States

Celdara Medical (OnCyte) Valuation and Funding

Deal Type Date Amount Post-Val Valuation/
EBITDA
Debt Status

This information is reserved for PitchBook Platform users. To explore Celdara Medical (OnCyte)‘s full profile, request access.

Request full access to PitchBook

Celdara Medical (OnCyte) Former Investors

Investor Name Investor Type Holding Participating Rounds Investor Since Board Seat Contact Info

This information is reserved for PitchBook Platform users. To explore Celdara Medical (OnCyte)‘s full profile, request access.

Request full access to PitchBook